Related Experiment Video
Updated: Jun 23, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
Published on: February 9, 2016
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo
Gautam Borthakur1, E Lin, Nitin Jain
1Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA. gborthak@mdanderson.org
Background:
Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports suggested similar outcomes for patients with de novo and secondary AML associated with core-binding factor (CBF) abnormalities.
Methods:
A total of 188 patients with CBF AML were analyzed. The frequency of secondary CBF AML was 9%.
Results:
Patients with secondary CBF AML were found to have significantly worse overall (OS) and event-free survival (EFS) compared with patients with de novo CBF AML. Secondary CBF AML status appeared to have only marginal significance in multivariate analysis.
Conclusions:
Matched analysis (by age, Eastern Cooperative Oncology Group performance status, and additional cytogenetic abnormality) indicated worse OS and EFS in patients with secondary CBF AML.
Related Concept Videos
Cancer Survival Analysis
Differentiation of Common Myeloid Progenitor Cells
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Regulation of Hematopoietic Stem Cells
Treatment Resistant Cancers
Treatment Resistent Cancers

